20-F: Portage Biotech Faces Going Concern Doubts Amid Strategic Restructuring and Clinical Program Pauses

Portage Biotech reported a significantly reduced net loss in Fiscal 2025 but continues to face substantial doubt about its ability to continue as a going concern, driven by ongoing capital constraints and strategic realignments of its clinical pipeline.

Summary

• Net loss for Fiscal Year 2025 decreased significantly to $6.8 million, down from $75.4 million in Fiscal Year 2024.
• Operating expenses decreased by $10.8 million, from $18.2 million in Fiscal Year 2024 to $7.4 million in Fiscal Year 2025, primarily due to reduced clinical trial and manufacturing costs.
• Cash and cash equivalents stood at $1.7 million as of March 31, 2025, and $0.6 million as of July 21, 2025.
• The company used $5.5 million in cash for operating activities in Fiscal Year 2025.
• A 1-for-20 reverse share split was effected on August 15, 2024, to comply with Nasdaq's minimum bid price requirement, which was successfully regained by June 24, 2025.
• The iNKT cell platform (PORT-2) development was deprioritized and its clinical trial closed in January 2024, with a Letter of Intent signed in December 2024 for potential acquisition of iOx Therapeutics Ltd. by Immunova LLC.
• Enrollment in the PORT-6 arm of the ADPORT-601 Phase 1b trial resumed in March 2025 after a temporary pause due to funding constraints, showing favorable safety and preliminary clinical activity.
• Preclinical efficacy data for PORT-7 in a murine mesothelioma model was promising, demonstrating anti-tumor activity as monotherapy and in combination with anti-PD-1 checkpoint blockade.
• Tarus Therapeutics, LLC was relaunched as Cyncado Therapeutics in January 2025, with Peter Molloy appointed CEO to secure external financing for the adenosine receptor antagonist portfolio.
• A private placement in January 2025 raised $2.15 million from two directors, Gregory Bailey and James Mellon.
• A stock-for-stock exchange with Compedica Holdings Limited in June 2025 resulted in Portage issuing 625,000 ordinary shares for a value of $5.0 million, with Compedica acquiring 27.4% ownership post-transaction.

Sentiment

Score: 2

Explanation: The company explicitly states significant doubt about its ability to continue as a going concern due to insufficient funding. While net loss decreased, it was primarily due to scaling back operations and impairments, not improved revenue or profitability. The reliance on future capital raises and strategic alternatives, with no guarantee of success, indicates a highly precarious financial position.

Positives

• Net loss significantly decreased to $6.8 million in Fiscal 2025 from $75.4 million in Fiscal 2024.
• Operating expenses were substantially reduced by $10.8 million in Fiscal 2025 due to strategic pauses in clinical programs.
• Regained compliance with Nasdaq's minimum $1.00 bid price requirement and shareholders' equity requirement.
• Resumption of patient enrollment in the final cohort of PORT-6 Phase 1a ADPORT-601 clinical trial, supported by favorable safety and preliminary activity signals.
• Promising confirmatory preclinical efficacy data for PORT-7 in a murine mesothelioma model, supporting its advancement.
• Relaunch of Tarus Therapeutics as Cyncado Therapeutics with a new CEO focused on external financing for the adenosine portfolio.

Negatives

• The company has incurred significant operating losses since inception and expects to continue doing so for the foreseeable future.
• Current cash and cash equivalents of $0.6 million (as of July 21, 2025) and potential ATM proceeds are insufficient to cover anticipated operating and funding requirements for the next twelve months, raising significant doubt about the company's ability to continue as a going concern.
• Development of the iNKT program (PORT-2) was deprioritized and its clinical trial closed due to ongoing capital constraints.
• Further advancement of PORT-7 monotherapy and PORT-6 + PORT-7 combination arms remains on pause, subject to available funding.
• The company has a significant accumulated deficit of $245.5 million as of March 31, 2025.
• Material weaknesses identified in internal controls over financial reporting, including inability to perform effective risk assessment, lack of skilled personnel for complex reporting, and insufficient written policies for accounting principles.

Risks

• Limited funding and uncertainty in ability to raise additional capital, potentially requiring delays, scope reduction, elimination, or divestment of research/development projects.
• Potential classification as a public shell company by Nasdaq, leading to delisting and negative consequences for trading and financing.
• Uncertainty of clinical trial outcomes, including potential side effects, lack of efficacy, and difficulties in patient enrollment.
• Reliance on third parties for manufacturing preclinical and clinical drug supplies, and potential issues with production yields, quality control, and regulatory compliance.
• Rapidly changing medical technology could render product candidates obsolete or less attractive.
• Dependence on collaborations with third parties for development, marketing, and commercialization, with no assurance of sufficient resource commitment or performance.
• Government actions on tariffs, trade policies, immigration, and research grants may impede research and capital raising efforts.
• Unpredictable and costly nature of protecting proprietary technology and maintaining licenses, with potential for challenges to patent validity or enforceability.
• Risks associated with identifying, consummating, or integrating acquisitions, including disruption, distraction of management, and increased indebtedness or dilution.
• Reliance on information technology and security systems, with risks of damage, interruption, or compromise from cybersecurity threats.
• Compliance risks and uncertainties under global data protection laws and regulations, potentially leading to investigations, fines, or reputational harm.
• Risks associated with doing business globally, including political, economic, operational, legal, and regulatory uncertainties.
• Loss of key personnel, given the limited number of officers and staff, and the part-time nature of the CEO's role.
• Regulatory uncertainty due to Brexit, potentially increasing costs and affecting business operations in the U.K. and EU.
• Inability to maintain compliance with Nasdaq listing requirements, leading to potential delisting.
• Dilution of ownership interest for existing shareholders from the issuance of additional ordinary shares.
• Significant control exerted by principal shareholders and senior management over matters subject to shareholder approval.
• Complex U.S. taxation rules for Passive Foreign Investment Companies (PFIC), potentially leading to additional taxes and reporting requirements for U.S. holders.
• Difficulty for U.S. shareholders to enforce civil liabilities against the company due to its British Virgin Islands incorporation and non-U.S. resident directors/officers.
• Reliance on home country governance practices as a foreign private issuer, which may afford less protection to shareholders than U.S. domestic companies.
• Impact of changing economic conditions, including inflation and increased cost of capital, on business, financial condition, and results of operations.

Future Outlook

The company continues to evaluate a broad set of strategic alternatives, including partnerships, asset sales, mergers, restructurings (in or out of court), company wind-downs, or new financing transactions. Future clinical development of programs like PORT-7 monotherapy and PORT-6 + PORT-7 combination arms is contingent on the availability of additional capital. The company does not anticipate directly engaging in the commercialization of product candidates it develops, instead aiming to monetize them through licensing, manufacturing and distribution, or outright sale.

Management Comments

• Our current cash resources will not cover all of our operational costs and the needs of our subsidiaries to progress towards and carry our clinical trials.
• We believe we will have to raise substantial amounts of additional capital from time to time, including in the near future, to continue our operations and to fund any of our product development, to conduct clinical trials, to obtain regulatory approval, to safeguard our intellectual property, and to commence any commercialization efforts that we may pursue in the future.
• There is no assurance that we will be able to raise the necessary funds from time to time, in the amounts that may be required, or on terms that are acceptable to us, to enable the company to pursue its operations, development or alternatives.
• We have incurred significant operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable.
• The process of reviewing strategic alternatives may require us to incur additional costs and expenses. It could negatively impact our ability to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction.
• There can be no guarantee that the process of evaluating strategic alternatives will result in our company entering into or completing a potential transaction within the anticipated timing or at all. There is no set timetable for this evaluation and we do not intend to disclose developments with respect to this evaluation unless and until we determine that further disclosure is appropriate or legally required.

Industry Context

Portage Biotech operates in the highly competitive and capital-intensive immuno-oncology sector, focusing on therapies that target resistance mechanisms to existing checkpoint inhibitors. The industry is characterized by rapid technological changes, high attrition rates in clinical trials, and significant funding requirements. The company's strategy of portfolio diversification and virtual infrastructure aims to mitigate inherent drug development risks, aligning with broader industry trends towards strategic partnerships and capital efficiency, especially for earlyto mid-stage assets. The focus on adenosine receptor antagonists and iNKT cell engagers positions the company in a niche aiming to address unmet needs in patients unresponsive to current standard-of-care immunotherapies.

Comparison to Industry Standards

• The company's approach of focusing on earlyto mid-stage, first-in-class therapies for various cancers, and monetizing through licensing or sale, is a common strategy for smaller biotech firms that lack the capital for full commercialization, similar to models seen in companies like PureTech Health.
• The strategic decision to pause and deprioritize clinical programs due to funding constraints is a common challenge for early-stage biotechnology companies, especially in the current capital market environment, and is not unique to Portage Biotech.
• The company's preclinical data for PORT-7 in mesothelioma, demonstrating superiority over single-agent anti-PD-1 antibody and enhanced activity in combination, suggests a competitive profile against established checkpoint inhibitors, which are a crowded market with at least 14 approved PD-1 antibodies from major pharmaceutical companies.
• The company's reliance on third-party contract research organizations (CROs) and manufacturers for clinical trials and drug supplies is standard practice for virtual or lean biotech companies, similar to many smaller competitors like Cullinan Oncology, Inc. and Black Diamond Therapeutics, which also outsource significant portions of their R&D.
• The high rate of attrition for product candidates proceeding through clinical trials is an industry-wide challenge, and Portage Biotech's experience with program pauses and impairments (e.g., iOx IPR&D, Tarus IPR&D, Stimunity) reflects this inherent risk in pharmaceutical development, comparable to setbacks faced by other companies in advanced clinical trials.

Management Changes

Corporate Governance

Legal Proceedings

• The former CEO, Ian Walters, instituted a mediation alleging unpaid severance payments. The company denies wrongdoing and expects litigation to be filed, which it intends to vigorously defend against.

Related Party Transactions

• Private placement on January 29, 2025, where 524,390 ordinary shares were sold for $2,150,000 to two directors, Gregory Bailey and James Mellon.
• SalvaRx Acquisition: Two company directors are also directors of SalvaRx Group plc, which owns approximately 2.2% of the company's shares.
• Stimunity: A Portage director serves on Stimunity's Supervisory Committee, and Portage's CSO is an External Scientific Advisor. Investment in Stimunity was written off to nil in Fiscal 2024.
• iOx: Management team of Portage comprises the management team of iOx. The company acquired the remaining 21.68% non-controlling interest in iOx on July 18, 2022, from minority shareholders (Sellers), issuing 53,500 ordinary shares and assuming contingent milestone obligations (Earnout Shares) of up to $25 million, which were written down to nil in Fiscal 2024 as the likelihood of achievement was remote.
• Saugatuck: A Portage director is the sole director of Saugatuck, a 70% owned subsidiary.
• Intensity: Former CEO served as a part-time officer of Intensity. Intensity provided services (primarily rent) to Portage. In Fiscal 2024, the company recovered $0.1 million for services in a settlement with Intensity.
• Portage Development Services Inc. (PDS): A wholly-owned subsidiary providing human resources and other services to operating subsidiaries via shared services agreements.
• Retention Agreements and General Releases: On July 22, 2024, the company entered into agreements with Allan Shaw (former CFO) and Joseph Ciavarella (consultant), paying an aggregate of $0.2 million in retention amounts and issuing 14,348 ordinary shares for accrued bonuses.
• Compedica Share Exchange: On June 5, 2025, the company issued 625,000 ordinary shares (valued at $5.0 million) to Compedica Holdings Limited, a company where Mr. Mellon is a director, in exchange for Compedica shares. Compedica acquired 27.4% ownership post-transaction. The company committed to use at least 50% of future equity financing to subscribe for new Compedica equity for 12 months.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and potential future equity issuances, including the recent private placement and ATM program.
• Shareholders are exposed to substantial financial risk due to the company's going concern doubt, accumulated deficit, and reliance on external funding.
• Employees and consultants have seen changes in compensation policies, including the adoption of a new director compensation policy and the non-approval of performance bonuses for Fiscal 2025 and 2024, potentially impacting morale and retention.
• Key employees, particularly senior management, are subject to increased pressure due to the company's strategic restructuring, funding challenges, and the need to attract and retain talent.
• Clinical trial participants may experience delays or discontinuation of programs, as seen with the iNKT program and pauses in the adenosine program, impacting access to potential new therapies.
• Creditors and suppliers face increased risk due to the company's liquidity challenges and going concern warning, potentially affecting payment timeliness and terms.
• Regulatory bodies (SEC, Nasdaq) are actively monitoring the company's compliance with listing standards and financial reporting, as evidenced by the Nasdaq non-compliance notice and subsequent regaining of compliance.

Next Steps

• Negotiate definitive agreements with Immunova LLC for the potential acquisition of iOx Therapeutics Ltd.
• Evaluate advancement of the PORT-7 monotherapy and PORT-6 + PORT-7 combination arms of the ADPORT-601 trial upon completion of the PORT-6 cohort, contingent on available funding.
• Secure external financing for Cyncado Therapeutics (formerly Tarus Therapeutics, LLC) to advance the adenosine receptor antagonist portfolio.
• Continue to explore a broad set of strategic alternatives, including partnerships, asset sales, mergers, restructurings, company wind-downs, or new financing transactions.
• Defend vigorously against potential litigation from former CEO Ian Walters regarding severance payments.
• Address material weaknesses in internal control over financial reporting, including risk assessment, skilled personnel, and written policies.

Key Dates

Recommendation

The company explicitly states 'significant doubt about the Company's ability to continue as a going concern' due to insufficient cash to meet anticipated operating and funding requirements for the next twelve months. While they are pursuing strategic alternatives and capital raises, there is 'no assurance' these efforts will be successful or on attractive terms. The history of substantial operating losses, accumulated deficit, and the need to pause/deprioritize clinical programs due to funding constraints indicate a highly distressed financial situation. Despite a reduced net loss, this was largely due to scaling back operations and impairments, not improved underlying business performance. For a seasoned investor, the fundamental risk of business failure outweighs any potential upside from preclinical data or strategic realignments, making a 'strong sell' recommendation appropriate.

Keywords

Immuno-oncology, Biotechnology, Clinical-stage, Adenosine receptor antagonists, iNKT cells, Cancer therapies, Drug development, SEC filing, Nasdaq, Going concern, Capital raise, Clinical trials, PORT-6, PORT-7, Cyncado Therapeutics, iOx Therapeutics, Strategic alternatives, Financial reporting, Risk management